The complexity of secondary cascade consequent to traumatic brain injury: pathobiology and potential treatments
Diabetes Nutr Metab 17:336342 Yasuda N, Inoue T, Nagakura T et al (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds
Can either compound be used by people
The glucagon receptor activity in retatrutide is what sets it apart from current treatments like Mounjaro (tirzepatide), which only targets GLP-1 and GIP receptors
For the deeper dive on candidacy, outcomes, and how these are used, see our guide to peptides for muscle growth, covering the growth hormone secretagogues used for lean mass and how a provider builds a supervised protocol around them
In a recent interview, Patricia Grigson, one of the lead investigators, said: The GLP-1 drugs reduced craving beginning with the lowest dose of liraglutide, even when patients were reporting high levels of stress